Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.

By Peter M. Rothwell, Michelle Wilson, C. Elwin, B. Norrving, Ale Algra, C. Warlow, T. Meade. The Lancet, 2010

1,314 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Shared Risk Factors in Cardiovascular Disease and Cancer (2016, background): “A meta-analysis looking at the association between aspirin and colorectal cancer found that aspirin reduced the risk of colorectal cancer by 24%.(102) Although aspirin’s benefits on the cardiovascular system have largely been attributed”
Differential Macrophage Programming in the Tumor Microenvironment (2012, neutral): “The importance of PGE2 in cancer is inferred from the preventative effects of cyclooxygenase-2 (COX-2) inhibitors including aspirin in colon [108, 109] and respective transgenic mouse models [108], as well as a less prominent effect in multiple other cancers [110].”
Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors (2019, background): “Nevertheless, the US Preventive Task Force does recommend low-dose aspirin for those over 50 years old with a heightened risk of cardiovascular disease or CRC [56].”